Market Access News | pharmaphorum

News

First drug for rare disease APDS cleared for NHS use

Pharming's Joenja has become the first disease-modifying drug that can be used by the NHS to treat APDS, an ultra-rare immunodeficiency disorder.

News

Roche joins the pharma firms planning big US investments

Roche will spend $50bn on manufacturing and R&D facilities in the US, with a pledge to export more medicines from the US than it imports.

Market Access

Sanofi's Dupixent gets FDA nod for chronic hives indication

Dupixent's seventh indication is chronic hives, where a new treatment hasn't been approved since Novartis's Xolair in 2014

Market Access

New FDA head says no more pharma on advisory committees

The announcement signals a new administration attempting to distance itself from industry, but the actual impact seems small.

News

WHO (sans US) finishes draft pandemic preparedness agreement

The WHO has concluded negotiations on a 30-page draft agreement on pandemic preparedness. It goes before the assembly for consideration in May.

News

Tariffs spelled out with Scrabble letters

Tariffs 'could cancel out discounts with biosimilars'

Tariffs on US pharma imports could remove discounts offered to health systems by biosimilars and threaten the future of the sector, says a non-profit.

First drug for rare disease APDS cleared for NHS use

Roche joins the pharma firms planning big US investments

Sanofi's Dupixent gets FDA nod for chronic hives indication

New FDA head says no more pharma on advisory committees

WHO (sans US) finishes draft pandemic preparedness agreement

Tariffs 'could cancel out discounts with biosimilars'

On genomics, NGS, and doing much more good than bad, with Ma...

How to meet your physicians where they are online

News

Editor's Picks